Objective: Advances in human oocyte cryopreservation have enabled this therapeutic modality to enter the clinical arena for pre–cancer treatment long-term female fertility preservation. In the last 2 years, our center and others have documented significantly increased oocyte survival (>85%) following cryopreservation and thaw. After completing an IRB-approved clinical study of oocyte cryopreservation and subsequent thaw, followed by successful implantation and five live births, our center initiated another IRB-approved clinical trial for long-term female fertility preservation. We report our initial experience with patients seeking pre–cancer treatment fertility preservation at our large academic reproductive center. Design: Retrospective data analysis. Materials and Methods: Data were reviewed from women presenting for pre–cancer treatment oocyte cryopreservation between January 2005 and November 2007. Variables analyzed included cancer diagnosis, time from initial consultation to cryopreservation cycle completion, cycle cancellation rate, patient age, number of cryopreserved oocytes, and oocyte maturity at cryopreservation. Characteristics of the variables were analyzed by statistical analysis. Results: Following the completion of an informed IRB consent, the approval of the treating oncologist, and all indicated precycle screening and counseling procedures, four cycles of oocyte cryopreservation were initiated in four pre–cancer treatment patients. The diagnoses for these patients included Hodgkin lymphoma, borderline malignant ovarian tumor, and myelodysplatic syndrome. Of the controlled ovarian hyperstimulation cycles initiated, none were canceled. Patient ages ranged from 23 to 32 years, with a mean of 26.2 ± 4.5. The mean number of oocytes cryopreserved was 17.8 ± 8.2. A total of 71 oocytes were retrieved and cryopreserved, of which 57 (80.3%) were metaphase II, 10 (14.1%) were metaphase I, and 4 (5.6%) were at the germinal vesicle stage. A quantity of ≥10 mature oocytes were retrieved and cryopreserved in 3 cycles. The average time between initial consultation and the completion of the cryopreservation cycle was 37.2 ± 22.5 days. A detailed breakdown of the results is included in the table:Tabled 1PatientABCDCancer diagnosisHodgkin lymphomaHodgkin lymphomaBorderline malignant ovarian tumorMyelodysplatic syndromeAge (yrs)32.723.325.323.4Time between initial consultation and cryopreservation (days)32197028Cryopreserved oocytes6192125Mature MII oocytes4142019MI oocytes2512GV oocytes0004 Open table in a new tab Conclusions: Our preliminary experience with offering pre–cancer treatment oocyte cryopreservation for fertility preservation resulted in four completed cycles. In our study, the mean number of oocytes retrieved across all patients was 17.8, though only three of the cycles yielded the optimal ≥10 mature oocytes for cryopreservation. The type of cancer, the short time from initial consultation to completed cryopreservation, and the generally good number of oocytes cryopreserved demonstrate that this is a good option for those patients seeking to preserve their fertility potential prior to cancer treatments. The patients presented with varying diagnoses and were scheduled to undergo different cancer treatments. The patients' oncologists were Supportive of their patients' desire to preserve their fertility despite the fact that gonadotropin hyperstimulation and oocyte retrieval slightly delayed the patients' cancer treatments. The average amount of time from initial patient presentation until the completion of the cryopreservation cycle was 37 days. Our analysis of these cycles suggests that the patient can be stimulated in a timely fashion for fertility preservation using oocyte cryopreservation. The improvement in survival rates of cryopreserved oocytes over the last 2 years makes this technique a good option for patients prior to cancer treatment. Oocyte cryopreservation allows a significantly improved chance of success for patients to have their own biological children after the treatment of cancer.